Physician profile
Jasmine Ross
NPI 1972959401
$724.71
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.15 · 2022: $275 · 2023: $276 · 2024: $89.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276 · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.82 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $115.89 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $85.29 | 2019-2023 | |
| Tactile Systems Technology INC | $57.05 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Daiichi Sankyo INC. | $45.49 | 2022-2023 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $43.27 | 2022-2023 | Alunbrig |
| Eisai INC. | $40.04 | 2022 | |
| Amgen INC. | $33.50 | 2019 | |
| Celgene Corporation | $31.22 | 2022-2023 | Pomalyst |
| Janssen Biotech, INC. | $28.64 | 2023 | |
| Sumitomo Pharma America, INC. | $24.76 | 2023 | Orgovyx |
| Seagen INC. | $24.34 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.03 | 2022 | |
| Beigene USA, INC. | $21.20 | 2023 | Brukinsa |
| Myovant Sciences INC. | $20.75 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.66 | 2023 | Libtayo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $19.41 | 2023 | Orserdu |
| Coherus Oncology, INC. | $17.47 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $17.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.98 | 2023 | |
| Glaxosmithkline, LLC. | $15.15 | 2022 | |
| Deciphera Pharmaceuticals INC. | $14.29 | 2023 | Qinlock |
| Genentech USA, INC. | $11.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.